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Abstract
The co-existence of impaired bone health (osteopenia/osteoporosis), reduced muscle mass and strength (sarcopenia), and 
increased adiposity (obesity) in middle-aged and older people has been identified in recent studies, leading to a proposal for 
the existence of “osteosarcopenic obesity” as a distinct entity. Evidence for the pathophysiological overlap of these condi-
tions is mounting, although a causal relationship is yet to be established. Each component condition occurs frequently with 
increasing age, and with shared risk factors in many instances, thus, an overlap of these three conditions is not surprising. 
However, whether the concurrent existence of sarcopenia, osteoporosis and obesity leads to an increased risk of adverse 
musculoskeletal outcomes and mortality above and beyond the risks associated with the sum of the component parts remains 
to be proven and is a question of research interest. In this article, we review evidence for the existence of osteosarcopenic 
obesity including the current operational definition of osteosarcopenic obesity, prevalence, pathophysiology, outcomes and 
exploratory approaches to the management of components. We conclude that, there is insufficient evidence to support a 
discrete clinical entity of osteosarcopenic obesity at this time. To expand knowledge and understanding in this area, there is 
a need for consensus on a definition of osteosarcopenic obesity which will allow for identification, further epidemiological 
studies and comparisons between studies. Additionally, studies should assess whether the clinical outcomes associated with 
osteosarcopenic obesity are worse than the mere addition of those linked with its components. This will help to determine 
whether defining a person as having this triad will eventually result in a more effective treatment than addressing each of 
the three conditions separately.
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Introduction
The rise in obesity prevalence over the last few decades 
poses a burdensome public health problem, with the com-
bined overweight and obese population in many countries 
accounting for the majority of people, especially among the 
middle-age and older-age groups [1, 2]. Typically, all con-
tributory factors to obesity, sarcopenia, and osteoporosis—
increase in fat mass, decrease in lean muscle mass and mus-
cle strength, and decrease in bone mass and function—occur 
with “normal aging”. Increased body fat can be present 
either as an overt overweight/obesity or fat redistributed into 
visceral organs and/or fat infiltrated into bone and muscle, 
which occurs especially with age and some chronic diseases 
[3, 4]. While reducing body weight is the primary strategy 
for obese individuals, weight-reduction therapies may com-
promise the ability to preserve muscle function and mass [5].
Sarcopenia, is a progressive and generalized skeletal mus-
cle disorder, which can be detected as low muscle strength 
and confirmed by the presence of low muscle quantity or 
quality [6, 7]. Sarcopenic individuals have both decreased 
muscle mass and increased intra- and intermuscular fat: 
changes that are associated with mobility limitations in older 
people [8]. The co-presence of sarcopenia and obesity has 
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been described in the literature as sarcopenic obesity [9]. 
Diminished physical performance leads to frailty, increased 
risk of falls, and subsequent fractures, causing a loss of inde-
pendence, reduced quality of life, and greater morbidity and 
mortality [10]. The risk of frailty and disability in obese 
individuals with low muscle mass and function has been 
reported to be higher than that observed in non-obese coun-
terparts with similar muscle alterations [11].
Osteoporosis, a systemic skeletal disease characterized 
by low bone mass and microarchitectural deterioration of 
bone tissue with a consequent increase in bone fragility, 
occurs frequently, particularly in older women. At the age 
of 50 years, the remaining lifetime probability of a major 
osteoporotic fracture in Sweden is 22% in men and 46% in 
women [12].
Sarcopenia and osteoporosis have similar risk factors 
that include genetics, endocrine function, and mechanical 
factors. Additionally, bone and muscle closely interact with 
each other not only mechanically but also metabolically. The 
combination of osteoporosis/osteopenia and sarcopenia has 
been termed osteosarcopenia [13–15]. It is unclear whether 
individuals with so-called osteosarcopenia are at greater risk 
of adverse clinical outcomes than those with sarcopenia or 
osteoporosis alone. In a small study of hip fracture patents, 
the 1-year mortality of those with osteosarcopenia (15.1%) 
was higher than that of those with osteoporosis alone (5.1%) 
or sarcopenia alone (10.3%) [16]. Consistent with this obser-
vation, a study of patients admitted to intensive care reported 
that 1-year mortality was increased in individuals with sar-
copenia, osteopenia or the combination compared with con-
trols [14]. In a study of 68 pre-frail adults, osteosarcopenic 
individuals showed a significant reduction in physical per-
formance compared with sarcopenic and osteopenic/osteo-
porotic individuals [17]. A large study of 5544 older men 
(mean age = 73.7 years) from the Osteoporotic Fractures in 
Men study showed that hazard for fracture compared with 
healthy controls was substantially greater for men with both 
low bone mineral density (BMD) and sarcopenia (3.8-fold) 
than for men with only one condition (1.1- to 1.7-fold) [18].
In contrast, a large cohort of community-dwelling men 
aged ≥ 70 years with combined osteopenia/osteoporosis 
and sarcopenia did not have an increased risk falls and 
fracture compared with those with either condition alone 
[19]. In a recent analysis, participants of the Women’s 
Health Initiative (WHI) were classified into mutually 
exclusive groups based on BMD and sarcopenia status 
[20]. Whereas low BMD was associated with increased 
risk of hip fracture, women with sarcopenia alone were 
at similar risk of hip fracture to non-sarcopenic women 
with normal BMD, suggesting that sarcopenia alone was 
not predictive of this outcome. In a further WHI study, 
appendicular lean mass was predictive of incident hip 
fracture amongst 872 participants aged 65 years or older 
who met Fried’s criteria for frailty, but this association 
did not remain statistically significant after adjusting for 
total hip BMD [21]. These findings are consistent with 
those of a study of 5911 older men and women in whom 
sarcopenia, was not associated with incident fractures or 
falls after adjustment for femoral neck BMD [22]. The 
disparate findings from these various studies may be in 
part related to the definitions used for osteoporosis and 
sarcopenia, but these observations do lead to the question 
of whether sarcopenia yields any information on fracture 
risk additional to that obtained from BMD.
Recent studies identifying the co-existence of impaired 
bone health (osteopenia/osteoporosis), reduced muscle mass 
or strength (sarcopenia), and increased obesity in middle-
aged and older women, have led to the proposal of “osteosar-
copenic obesity” as a distinct entity [3]. In this classification, 
osteosarcopenic obesity is described as the most advanced 
stage in a conceptual model of bone, muscle, and fat tissues 
in healthy and disease states resulting from aging, or individ-
ual comorbidities [23]. Each component of osteosarcopenic 
obesity occurs frequently with increasing age, and with 
shared risk factors; thus, an overlap in prevalence is not sur-
prising. However, whether the concurrent existence of sar-
copenia, osteoporosis and obesity leads to an increased risk 
of adverse outcomes including mortality above and beyond 
the risks associated with the sum of the component parts 
remains to be proven and is a question of research interest. 
In this article we critically review evidence for the existence 
of osteosarcopenic obesity, including definition, prevalence, 
pathophysiology, outcomes and exploratory approaches to 
the management of components.
Methods
Articles included in this narrative, critical literature review 
were identified through literature searches of PubMed, Sco-
pus, and Embase using the following MeSH items or free 
words: “osteoporosis”, “sarcopenia”, “obesity” “osteosarco-
penia”, “osteosarcopenic obesity”; additional terms searched 
for in either the title, abstract or keywords included: “defi-
nition”, “epidemiology”, “pathophysiology”, “hormones”, 
“exercise”, “nutrition”, “non-pharmacological”, “pharma-
cological”. The search strategy was limited to studies con-
ducted in humans, publications in English language, and 
full-length articles published from inception until January 
15, 2018. Finally, the methodological sections and reference 
lists of relevant articles (particularly review articles) were 
scrutinised (by JB, EMD, RF, JMK, FL, SM, SP, JYR, PS) 
for potentially interesting articles. The process for literature 
identification and selection of the final number of references 
included in this paper is outlined in Fig. 1.
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Epidemiology
A few studies have appeared in the literature reporting 
on the epidemiology of osteosarcopenic obesity. How-
ever, without a standardised definition of osteosarcopenic 
obesity it is difficult to make comparisons and draw con-
clusions on prevalence of as the published studies use 
multiple definitions for the osteosarcopenic obesity com-
ponents (Table 1) [24–26].
Definitions
Obesity
Overweight and obesity are defined as abnormal or excessive 
fat accumulation that presents a risk to health. Body mass 
index (BMI) provides a crude measure of obesity—defined 
as a person’s weight (in kilograms) divided by the square 
of his/her height in metres; the World Health Organization 
(WHO) defines obesity in a person with a BMI of ≥ 30 kg/
m2, while a person with a BMI ≥ 25 kg/m2 and < 30 kg/m2 is 
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Fig. 1  Literature selection process. OSO, osteosarcopenic obesity
Table 1  Multiple definitions of osteosarcopenic obesity components used in clinical studies
ALM appendicular lean mass, ALM/ht2 appendicular lean mass index normalised for height, FNIH Foundation for the National Institutes of 
Health, SD standard deviation
Study Osteopenia/osteoporosis Sarcopenia Obesity
Szlejf et al. [24] At least one T-score ≤ –1 FNIH criteria:  ALMBMI < 0.512 and grip 
strength < 16 kg in women
Fat mass: 35% body fat if < 60 years; 40% if 
> 60 years (females)
Chung et al. [25] At least one T-score ≤ –1 ALM/ht2 < 2 SD below sex-specific young adult 
mean
Fat mass > 30% in males or > 40% in females
Ilich et al. [26] At least one T-score ≤ –1 ALM residual value of < 1.43 (20%) Fat mass ≥ 35% (females)
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considered as overweight [27]. An alternative definition of 
obesity based on body fat percentage is not well established 
and has arbitrary cut-off points [28]: the WHO proposes 
≥ 35% body fat for women < 60 years [29] and > 40% body 
fat for women aged ≥ 60 years and older [30].
Sarcopenia
Currently, there is no international consensus on the opera-
tional definition of sarcopenia, and several definitions of 
sarcopenia are used with consequent impact on the preva-
lence of sarcopenia [6, 31–34]. For example, a study of 445 
community-dwelling seniors (mean age 71 years, 45% men) 
examined the prevalence of sarcopenia using seven avail-
able definitions of sarcopenia plus two related definitions. 
The prevalence of sarcopenia varied between 2.5 and 27.2% 
among women, and 3.1 and 20.4% among men [33].
The European Working Group on Sarcopenia in Older 
People (EWGSOP) is one of the most widely used concep-
tual and operational definitions of sarcopenia [6] but dif-
ferent cut-off points were recommended for diagnosis for 
muscle mass, muscle strength and gait speed. In a sample 
of hospital referees aged ≥ 65 years the prevalence of sar-
copenia varied two-fold from 9% to 18% depending on the 
cut-offs applied [35]. Thus, the basis for defining variants of 
sarcopenia are based on questionable foundations.
Recently, the EWGSOP2 has published a revised Euro-
pean consensus on the definition and diagnosis of sarcopenia 
to delineate clear criteria and tools that define and character-
ize sarcopenia in clinical practice and research populations. 
The EWGSOP2 guidelines focus on low muscle strength as 
the primary parameter to detect sarcopenia; the diagnosis is 
confirmed by the presence of low muscle quantity or qual-
ity, and when all three qualities are detected sarcopenia is 
considered as severe. In addition, the EWGSOP2 provides 
clear cut-off points for measurements of variables that iden-
tify and characterize sarcopenia [7].
Osteoporosis
Notably, the definitions employed for the bone component 
of osteosarcopenic obesity have included both osteopenia 
and osteoporosis, and consequently may capture a very large 
proportion of the population of women aged over 50 years. 
In Sweden, for example, the prevalence of osteopenia is 
approximately 70% of women aged ≥ 50 years, whereas the 
prevalence of osteoporosis is 21% [12]. Osteopenia is meas-
ured using BMD and based on the lowest T-score of the 
posteroanterior spine, femoral neck, trochanter, or total hip 
(T-score between 1.0 and 2.5 standard deviations [SD] below 
the mean adult value) [36]. Osteoporosis is measured as the 
T-score for BMD assessed at the femoral neck (reference 
site) and defined as BMD 2.5 SD or more below the mean 
adult value [36, 37].
Diagnostic Techniques
Dual-energy X-ray absorptiometry (DXA) is commonly used 
in clinical practice and epidemiological studies to assess 
body composition, in terms of bone, non-fat mass and fat 
mass (Table 2). Regional bone density is measured using 
DXA of the lumbar spine, femoral neck or total hip. Mus-
cle mass is determined from DXA whole body scan which 
estimates lean mass (i.e. muscle, water, fibrous tissue and 
viscera) [6, 31, 32]. The composite Short Physical Perfor-
mance Battery (SPPB) is the most widely used test of overall 
physical performance [23, 38]. Other techniques employed 
for exploration of the pathophysiology of the interactions 
between bone, muscle and fat include bioelectric imped-
ance analysis (BIA) and magnetic resonance imaging (MRI). 
MRI and computed tomography are used experimentally to 
assess muscle fat infiltration, which may be important when 
considering osteosarcopenic obesity. Anthropometric meas-
urements (e.g. mid-upper arm circumference) may be used 
to assess obesity, but have suboptimal correlation with other 
methods.
Reported Prevalence of Osteosarcopenic Obesity
Given the heterogeneous approach to the definitions of 
sarcopenia, osteosarcopenia and obesity, defining the 
prevalence of osteosarcopenic obesity is problematic. A 
prevalence of 12–19% of osteosarcopenic obesity has been 
reported in women aged over 50 years [24–26]. A Mexican 
study of women aged ≥ 50 years (N = 434) found a preva-
lence of 19% and osteosarcopenic obesity was associated 
with frailty and poor physical performance [24]. Another 
study among postmenopausal women of mean age 63 years 
found a prevalence of osteosarcopenic obesity of 12.1% 
and an association with poorer functionality in women 
Table 2  Methods to assess osteosarcopenic obesity components
BIA bioelectric impedance analysis, BMI body mass index, DXA dual-
energy X-ray absorptiometry, SPPB short physical performance bat-
tery
Primary measure Secondary measure
Osteopenia/osteo-
porosis
DXA
Sarcopenia DXA
Grip strength
Gait speed
BIA
SPPB
Obesity DXA BMI
Waist circumference
BIA
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presenting with osteosarcopenic obesity, particularly com-
pared to obese women, increasing the risk for bone frac-
tures and immobility due to the combined decline in bone 
and muscle mass, and increased fat mass [26]. Investigation 
of the Korean National Health and Nutrition Examination 
Survey (including N = 3385 men and N = 4064 women aged 
> 50 years) found the incidence of sarcopenia, sarcopenic 
obesity, and osteosarcopenic obesity as 31.5%, 5.1%, and 
4.1%, respectively. Sarcopenic obesity was associated with 
increased odds for the development of osteoporosis among 
the middle-aged and older-aged Korean population [25].
Obesity at a young age may also contribute to the early 
development of osteosarcopenic obesity and frailty sooner 
than that which occurs in a lean population. Overweight/
obese but otherwise healthy young adults (aged 18–21 years) 
exhibit ‘osteosarcopenic elements’ including: increased fat 
mass, and decreased muscle and bone mass compared with 
lean controls [39].
Pathophysiology
Recent evidence suggests a potential interconnection 
between osteoporosis, sarcopenia, and obesity with shared 
pathophysiology [40]. The changes in body composition that 
occur over a lifetime, and interplay between mechanisms 
leads to progressive losses of bone and muscle mass and an 
increase in adipose tissue (Fig. 2) [40]. An increase in total 
and/or abdominal adipose tissue causes an increase in pro-
inflammatory cytokines, as well as hormonal disturbances 
leading to losses of both muscle and bone tissues through a 
variety of mechanisms which ultimately affect clinical out-
comes, such as an increase in risk for falls and fractures [40].
Bone and muscle are physically and functionally coupled. 
Several age-related alterations of bone microenvironment 
and an altered bone-muscle cross-talk are proposed to be 
relevant contributors to loss of bone strength and mass char-
acteristic of osteoporosis [41]. Insulin-like growth factor-I 
(IGF-I), myostatin, and cytokines (e.g., interleukin-6 [IL-
6]), collectively referred to as myokines, are released from 
skeletal myocytes and exert actions on the muscle and the 
bone. Analogously, osteokines, including osteocalcin, osteo-
protegerin and bone matrix proteins are released from bone 
cells and participate in the regulation of musculoskeletal 
homeostasis [41].
The reductions in muscle and bone tissues are associated 
with decreases in physical activity; once losses hit a thresh-
old, physical activity becomes even more limited leading 
to a vicious cycle of progressive loss of muscle and bone 
as well as gain in fat [40]. While age-related changes may 
be considered of primary importance, other important fac-
tors may include endocrine disorders, inadequate nutrition, 
inflammation, neurodegenerative disorders, physical inactiv-
ity, and other chronic and lifestyle factors [42].
Hormonal Aspects
There are cumulative hormonal changes that occur with 
aging and obesity, such as a substantial decrease in levels 
of the main anabolic hormones. Hormonal players that are 
identified as having a potential role in development of the 
components of osteosarcopenic obesity are listed in Table 3 
[42]. Changes in anabolic hormones have been associated 
with unfavourable changes in muscle mass, muscle func-
tion and impaired functional capacity. Testosterone has a 
dose-dependent impact on fat-free mass in both the young 
and old, with higher levels associated with reduction in fat 
mass and increase in skeletal muscle mass and strength [43]. 
Low levels of testosterone, but not oestradiol, predict frailty 
in older men and are associated with incident falls [44–46].
Non-androgenic anabolic hormones predict the risk of 
frailty in aging men, including IGF-I, dehydroepiandros-
terone, parathyroid hormone, and 25-OH vitamin D [47]. 
Age-related decreases of serum levels of adrenal androgens 
are shown in healthy men and women [48, 49]. Higher levels 
of cortisol are detected in frail older women, with blunted 
diurnal variation in cortisol levels compared with non-frail 
individuals [50]. Increasing age is also shown to influence 
24-h integrated concentration of growth hormone in normal 
individuals [51].
Increasing age and obesity both contribute to sarcopenia, 
for which a postulated mechanism involves disturbed insulin 
signalling and insulin resistance [9]. Frailty and sarcopenia 
are newly emerging and high impact complications of dia-
betes [52]. Both diabetes and obesity impact on muscle loss 
[52], and muscle mass is inversely associated with insulin 
Fig. 2  The interplay between bone, muscle and adipose tissue. GH, 
growth hormone; IMAT, intramuscular adipose tissue; IGF, insulin-
like growth factor; ROS, reactive oxygen species. Reproduced from: 
Ormsbee MJ et al. Osteosarcopenic obesity: the role of bone, muscle 
and fat on health. J Cachexia Sarcopenia Muscle (2014) 5:183–192. 
Reproduction permitted under the terms of the Creative Commons 
Attribution‐NonCommercial License
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resistance and prediabetes [53]. Hyperglycaemia predicts 
persistently lower muscle strength with aging [54], and an 
excessive loss of skeletal muscle mass has been detected in 
older adults with type 2 diabetes [55]. In the obese state, 
dysregulation of adipokines that contribute to muscle main-
tenance in the lean state leads to sarcopenia [9].
Mechanisms responsible for the development of osteosar-
copenic obesity components are complex and may include 
multiple factors: endocrine versus local regulation, thresh-
old effects, hormonal implications of comorbidities, and 
cross-talk between endocrine-immune-neurologic factors. 
Bidirectional interactions between hormonal changes and 
altered body composition are identified but uncertainties 
remain as to causalities versus reverse causalities, and bidi-
rectional interactions create conditions for self-amplifying 
vicious circles. While many potential and biologically plau-
sible contributing mechanisms are postulated, indicating a 
likely multifactorial pathogenesis, biologically plausible 
hypotheses have not yet established a clinical relevance for 
pathophysiology, prevention, or treatment. Furthermore, 
there is a need for unravelling of the complex ‘local’ fat-
muscle–immune system interactions and their interaction 
with systemic hormones and neurogenic factors.
Nutritional Aspects
The role of nutrition in the development of osteosarcopenic 
obesity components is significant. Middle-aged and older 
women who eat a healthy diet are less likely to have multiple 
body composition abnormalities [56]. The typical Western 
diet and lifestyle promotes several chronic diseases includ-
ing the components of osteosarcopenic obesity, by facilitat-
ing a pro-inflammatory state, largely via the imbalance in 
omega-6/omega-3 polyunsaturated fatty acid (PUFA) ratio 
and low-fibre and high-processed food consumption [57], 
which is linked to a higher risk of frailty and fractures [58, 
59]. A Western pattern diet is linked to a higher risk of sar-
copenia in menopausal women as compared with a Medi-
terranean pattern diet (high in low-fat dairy, vegetable, fish, 
nut, olive and vegetable oil), which is associated with lower 
risk [60]. Greater adherence to a Mediterranean pattern diet 
is associated with less loss of skeletal muscle mass and lean 
body mass, better physical performance [61], a significant 
reduction in waist circumference [62], and a lower incidence 
of frailty [63].
Deficiencies in macronutrients are important, specifically 
protein and amino acid intake (in particular the branched 
amino acids) in terms of quantity, quality (type of protein, 
essential amino acids, and absorption rate) and timing of 
intake. Energy imbalances in aging, excessive high glycae-
mic carbohydrate, lower protein intakes and low long-chain 
PUFA intakes may contribute to the components of osteo-
sarcopenic obesity [64]. Dietary protein intake contributes 
to maintenance of lean muscle mass and may be a modifiable 
risk factor for sarcopenia in older adults [65]. Protein intakes 
of ≥ 1.0 g/kg body weight/day may be optimal for maintain-
ing lean mass and physical function in older adults [66].
Deficiencies in multiple micronutrients may be important 
in osteosarcopenic obesity, in terms of intake, absorption, 
and bioavailability [67]. Obese adults are shown to have 
lower micronutrient intake and higher prevalence of micro-
nutrient inadequacy as compared with normal weight adults 
[68]. Low serum vitamin D level in mid- and later-life is 
associated with multiple indices of adverse body composi-
tion [69].
Summarizing the above, it has to be acknowledged that 
very few studies have specifically addressed nutritional 
intake in the context of osteosarcopenic obesity. Most of 
the presented information has been derived from studies that 
focused separately on sarcopenia, osteoporosis or obesity.
Health Outcomes
Although understanding of the aetiology, prevalence, and 
consequences of osteosarcopenic obesity components are, 
so far, limited, it is reasonable to infer a negative impact in 
an aging, and increasingly obese population. The potential 
clinical consequences of osteosarcopenic obesity are linked 
to each of the underlying conditions, with the possibility 
of interaction to increase further the adverse health effects. 
Clinical outcomes associated with osteosarcopenic obesity 
Table 3  Hormonal players 
identified with a potential 
role in the development of 
osteosarcopenic obesity 
components
BMP bone morphogenetic protein, FGF fibroblast growth factor IGF-I insulin-like growth factor, IL inter-
leukin, MCP-1 monocyte chemoattractant protein-1, TNF-α tumour necrosis factor-α
Hormone class Examples
Anabolic Somatotropic axis, sex steroids
Adrenal cortex Cortisol, adrenal androgens
Insulin
 Adipokines TNF-α, IL-6, adiponectin, BMPs, IL-13, IL-15, IL-10, leptin, resistin, 
chimerin, myostatin
 Myokines Myostatin, irisin, BMPs, FGF-21, IL-10, MCP-1, TNF-α, IL-6, IL-1β, IGF-I
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components include: increased risk of fractures, impaired 
functional status (including activities of daily living) [70, 
71], physical disability, insulin resistance, increased risk of 
infections, increased length of hospital stay, and reduced 
survival [40]. However, there is little evidence to date on 
an additive or multiplicative health impact of osteoporosis 
in a distinct overlap with obesity and sarcopenia. The cas-
cade of metabolic abnormalities associated with changes in 
body composition related to osteosarcopenic obesity com-
ponents may also be important in younger populations with 
comorbidities such as diabetes mellitus, glucocorticoid use, 
or malignancy.
Frailty is a geriatric syndrome resulting from age-related 
declines across multiple physiological systems leading to 
increased risk of falls, hospitalisation, institutionalisation 
and mortality [72, 73]. Frailty and sarcopenia overlap in 
terms of physical factors [74], and osteoporosis is linked 
to frailty [75]. The link between obesity and frailty is less 
clear and complex. Osteosarcopenic obesity components 
occur frequently in middle-aged and older women and are 
independently associated with frailty and poor physical per-
formance; women with osteosarcopenic obesity have lower 
functional abilities and higher frailty scores compared with 
their counterparts without osteosarcopenic obesity [24].
Body Fat Location: Distinguishing Between Visceral 
and Subcutaneous Adipose Tissue
The location of body fat may have differential impact upon 
health outcomes. Abdominal obesity is more closely associ-
ated with incidence of frailty than general obesity in older 
people [76]. Among a sample population of older people 
(N = 801), the prevalence of osteosarcopenic obesity was 
determined as 6.8%; subjects with a visceral/subcutaneous 
adipose tissue ratio > 1 were classified as having visceral 
obesity, and subjects with values under 1 were classified 
as having subcutaneous obesity [77]. Visceral obesity was 
closely linked to a higher risk of fractures and inflammation 
[77].
Management of Osteosarcopenic Obesity 
Components
No clinical studies are currently available that have tested 
therapeutic approaches in individuals with osteosarcopenic 
obesity. The components of osteosarcopenic obesity occur as 
a result of sedentary behaviour and a lack of regular physical 
activity, among other factors. Consequently, the therapeutic 
approach should include a combination of tailored exercise, 
optimised nutrition, and pharmacotherapy targeted at the 
three components.
Exercise
Multidimensional treatment protocols should include a pro-
gramme of multimodal exercise comprising the elements of 
balance, aerobic and resistance exercise. Mobility-limited 
older individuals have a distinct muscle phenotype of poor 
muscle quality and intermuscular fat accumulation. The rise 
in intermuscular fat found in sarcopenia may be suppressed 
by physical activity [78]; mobility-limited older people have 
a greater change in intermuscular adipose tissue over time 
[8]. Moderate-intensity physical activity programmes sig-
nificantly improve physical functioning in mobility-limited 
older adults, attenuate intermuscular fat accumulation and 
improve muscle quality. A lifestyle intervention study of 
aerobic and resistance exercise versus health education 
in older people (aged 70–89 years) resulted in a positive 
improvement in physical activity (SPPB) over an average of 
2.7 years follow-up [79]. A study of the effects of a 12-week 
program of resistance training in older women (N = 62, mean 
age 68 years; mean BMI 27 kg/m2) found that performing 3 
sets of each exercise 3-times weekly has beneficial effects on 
the risk factors for osteosarcopenic obesity including skel-
etal muscle mass and strength. Moreover, moderate-intense 
physical exercise is an important stimulus for osteoporosis 
prevention and treatment [80].
Nutrition
Nutritional interventions to prevent and/or alleviate osteosar-
copenic obesity components include: adequate intake of pro-
tein (> 0.8 g/kg/day), calcium (1200 mg/day), magnesium 
(320 mg/day), and vitamin D (800 IU/day), and increasing 
consumption of foods containing omega-3 PUFAs (1 g/day) 
and fibre (25 g/day for women) [57, 81]. There is evidence 
for a higher protein requirement in older people (1.0–1.2 g/
kg/day), due to a blunted muscle protein synthetic response 
to protein ingestion, and higher protein intake is recom-
mended in those who are exercising (≥ 1.2 g/kg/day) and 
in older adults with acute or chronic diseases (1.2–1.5 g/
kg/day) [81–83]. Dietary protein quality is also important. 
Leucine supplementation enhances myofibrillar protein syn-
thesis in older men consuming lower- and higher-protein 
diets with and without exercise [84]. Increased protein intake 
(> 0.8 g/kg/day) is known to increase BMD in older people 
with osteoporosis [81, 85].
Vitamin D deficiency is associated with osteosarcopenic 
obesity components [69, 86]. The combined intervention of 
a vitamin D with high whey protein, leucine-enriched oral 
supplement has resulted in improvements in muscle mass 
and lower-extremity function as well as in a decrease in 
fat mass among sarcopenic older adults [87, 88]. Omega-3 
PUFAs may influence skeletal muscle health and func-
tion [89], and correlations are found between omega-3 and 
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omega-6 PUFAs, protein intake, BMD and physical perfor-
mance [90]. Omega-3 PUFA supplementation increases the 
rate of muscle protein synthesis in older adults [91].
It is as yet unclear how high protein diets impact on body 
weight, and how dietary intervention can improve bone, 
muscle and fat all together, for which further studies are 
warranted.
Combined Exercise and Nutrition
Older adults who exhibit osteosarcopenic obesity compo-
nents may benefit from combined efforts to improve diet 
(as specified above) and physical activity involving aerobic, 
strength, flexibility and balance training, which requires 
further investigation [57]. Together these can positively 
influence intermuscular fat accumulation and improve mus-
cle quality with equivocal effects on physical functioning. 
Supplementation with whey protein, essential amino acids 
and vitamin D, in conjunction with age-appropriate exercise, 
is shown to increase fat-free mass and strength, and boost 
nutritional status, physical function and quality of life in 
sarcopenic older persons (mean age 80 years) with only a 
12-week program [92]. In the VIVE-2 study a combination 
of exercise intervention (3 times per week for 6 months) and 
nutritional supplementation with whey protein (20 g), vita-
min D (800 IU), calcium, vitamins and minerals (150 kcal) 
among people aged 70 + years, led to an increase in muscle 
density and a reduction in intermuscular fat [78, 93, 94].
Gut Microbiota
Increasing evidence suggests a role for altered gut micro-
biota on inflammation, obesity, and other chronic conditions. 
A connection between osteosarcopenic obesity components 
concurrent with altered microbiota in older individuals, par-
ticularly those living in long-term care facilities, has been 
established [95]. The gut microbiota may be a new thera-
peutic target in muscle wasting [96]. The gut microbiota 
can modulate amino acid availability; antibiotics have been 
shown to increase levels of circulating amino acids, which 
would have been otherwise degraded by intestinal bacteria 
[97].
Pharmacotherapy
Research interests have focused on pharmacological agents 
to separately address the three components of osteosarco-
penic obesity. Medications available to reduce obesity have 
limited effects and are yet to be properly tested in older 
people [98, 99]. Drugs available for the prevention and 
treatment of osteoporosis impact upon BMD and fracture 
risk, although their effect on muscle or fat mass is not well 
studied [100, 101]. Multiple pathways are involved in the 
loss of muscle mass arising from aging, malnutrition, obe-
sity, inflammation and inactivity, which offers many targets 
for therapeutic intervention [102].
Several pharmacological agents are currently under inves-
tigation to manage sarcopenia e.g., testosterone, selective 
androgen receptor modulators (SARMs), AMP-activated 
protein kinase (AMPK) agonists, activin 11R antagonists, 
growth hormone, IGF-I analogues, and ghrelin-modulating 
agents [103]. Targeting pathways that centrally regulate both 
bone and muscle (e.g. growth hormone, IGF-I, sex steroids), 
and newly emerging pathways that facilitate communica-
tions between these two tissues (e.g. activin/myostatin) 
might allow a greater therapeutic benefit in frail older people 
[104]. To aid future development of new therapeutic targets 
for sarcopenia, recommendations for the conduct of clinical 
trials have been developed, along with the proposal for a 
core outcome set to include the domains of activity/inde-
pendence, quality of life, costs, and muscle mass, strength 
and performance [105, 106].
Testosterone
Pharmacological treatment effects with anabolic hormones 
can be demonstrated but are rather mitigated and of uncer-
tain clinical significance alongside some safety concerns. 
Several trials conducted with testosterone show a direct 
effect on muscle mass and, in several cases, on muscle 
strength and performance, with a slight reduction in body 
fat, and some effect on bone density [107–110]. Testosterone 
supplementation is also shown to benefit other aspects of 
health, including sexual function, physical function, vital-
ity, quality of life and improved mood [109, 111]. However, 
when considering testosterone replacement therapy, the 
potential benefits of treatment must be weighed against the 
possible side effects [112, 113], and the broad application 
of testosterone therapy in older men with low testosterone 
level is not recommended [114].
Selective Androgen Receptor Modulators (SARMs)
SARMs have the same anabolic effect on muscle tissue as 
testosterone. These new drugs may expand the clinical appli-
cation of androgens in sarcopenia as they enter the clinical 
phase of research, although to date there are few studies. 
Treatment with ostarine (enobosarm) for 3 months is dem-
onstrated to increase muscle mass and stair climbing power 
in healthy older men and postmenopausal women [115].
Growth Hormone
Many studies reported only marginal effects of growth hor-
mone (GH) supplementation on skeletal muscle mass, bone 
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density, fat mass and physical function [116]. Most stud-
ies have documented that GH supplementation is ineffec-
tive in older subjects, by increasing muscle mass but not 
muscle strength [117–119]. Moreover, the majority of tri-
als conducted on GH supplementation have reported a high 
incidence of adverse effects [116, 118, 119]. Consequently, 
GH treatment should not be considered as a safe strategy 
to improve body composition and functionality in older 
individuals.
Ghrelin Agonist
Ghrelin concentrations have been reported to be strongly 
correlated with the amount of skeletal muscle mass. An 
enhanced ghrelin blood concentration results in an increased 
sensation of hunger and food intake. Considering that ano-
rexia and malnutrition are important causes of sarcopenia, 
it has been hypothesised that ghrelin supplementation could 
be effective. Very few clinical studies on synthetic ghrelin 
or ghrelin agonist treatment have been conducted in older 
subjects. In healthy older adults, without sarcopenia, 2 years 
of an oral ghrelin mimetic agent (ibutamoren mesylate; 
MK-0677) increased the GH and IGF-I blood levels and 
muscle mass but without significant changes in strength or 
physical function [120]. In other studies of ibutamoren in 
persons with hip fracture the increase in plasma IGF-I lev-
els was not paralleled by improvement in most functional 
performance measures, and one trial was terminated early 
due to a safety signal of congestive heart failure [121, 122].
Myostatin Inhibitors
Myokines are involved in communication pathways from 
skeletal muscle to bone [123]. Myostatin (growth differen-
tiation factor-8) is a member of the transforming growth 
factor-β (TGF-β) superfamily that is expressed almost exclu-
sively in skeletal muscle. Myostatin inhibits myoblast pro-
liferation and thus acts as a negative regulator of skeletal 
muscle mass.
At present, limited data is available from human studies 
of myostatin inhibitors [124]. Bimagrumab increased total 
thigh muscle volume and appendicular muscle mass in sar-
copenic older persons (N = 40) [125]. In parallel, decreases 
in intermuscular thigh adipose tissue of 9.5% and 3.8% in 
subcutaneous thigh fat were measured at 24 weeks [125]. 
Participants with slower walking speed at baseline receiving 
bimagrumab had greater improvements in gait speed (mean 
0.15 m/s, p = 0.009) and 6-min walk distance (mean 82 m; 
p = 0.022) than those receiving placebo [125]. In addition, 
bimagrumab improved body composition and insulin sen-
sitivity in insulin-resistant individuals [126]. This initial 
proof-of-concept data still needs to be confirmed in larger 
pivotal trials.
Angiotensin‑Converting Enzyme (ACE) Inhibitors
The effects of ACE inhibitors on muscle function have been 
mainly attributed to positive cardiovascular effects. There 
is contrasting data from observational studies and RCTs for 
the effect of ACE inhibition on skeletal muscle. Among 95 
participants that completed a 20-week trial, the mean 6-min 
walking test was significantly improved in subjects receiving 
perindopril relative to the placebo group (mean between-
group difference 31 m) [127]; while another trial reported no 
beneficial effect on physical performance in older subjects 
receiving an ACE inhibitor for 6 months [128]. A combined 
study of leucine and ACE inhibitors as therapy for sarcope-
nia (LACE trial) is underway [129].
Discussion
A review of the current literature shows that while data is 
accumulating for the existence of osteosarcopenic obesity 
as a distinct entity a number of questions remain, not least 
the clinical relevance of identification of such a condition. 
A progressive loss of bone and muscle mass and increase in 
adipose tissue occurs with normal aging. Thus, identification 
of the epidemiological overlap of osteoporosis, sarcopenia, 
and obesity is perhaps not surprising given the common risk 
factors and increasing prevalence of these conditions in older 
age. Evidence for the pathophysiological overlap of these 
conditions is expanding, which may occur through an inter-
play of inflammatory and hormonal mechanisms. However, 
a causal relationship between the osteosarcopenic obesity 
components is yet to be identified, and more comprehensive 
research to understand the underlying biological phenomena 
linking the three conditions is needed.
Whether osteosarcopenic obesity should be distinguished 
as a distinct condition, separate from osteosarcopenia or sar-
copenic obesity remains to be determined. Additional stud-
ies should assess whether the clinical outcomes associated 
with osteosarcopenic obesity are worse than the mere addi-
tion of those linked with its components. Consequently, this 
will help to determine whether defining a person as having 
this triad will result in better treatment and outcomes than 
addressing each of the three conditions separately.
In conclusion, we consider that there is insufficient evi-
dence to support a discrete clinical entity of osteosarcopenic 
obesity at this time. To expand knowledge and understanding 
in this area, there is a need for consensus on a definition of 
osteosarcopenic obesity, which will allow for identification, 
further epidemiological studies and comparisons between 
studies. A critical first step in this process requires further 
research to standardise the operational definition of osteo-
sarcopenic obesity components (sarcopenia and obesity). 
Furthermore, research is needed to confirm or reject the 
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hypothesis that the identification of osteosarcopenic obesity 
adds anything to the concept of osteosarcopenia plus obesity, 
in terms of clinical outcomes and therapeutic guidelines.
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